Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK beats Q4 earnings estimates, lifts 2031 sales target
02:17am, Wednesday, 05'th Feb 2025
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division.
Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc
08:40pm, Tuesday, 04'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit in the U.S. District Court for the Eastern Dis
AstraZeneca and GSK put spotlight on pharma as results loom
10:46am, Thursday, 30'th Jan 2025
AstraZeneca PLC and GSK PLC will bring the pharmaceutical sector into the spotlight when both report next week. For AstraZeneca, full-year figures on Thursday, February 6 come after its shares have re
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
11:05am, Wednesday, 29'th Jan 2025
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
09:40am, Wednesday, 29'th Jan 2025
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
08:00am, Wednesday, 29'th Jan 2025
Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS. The post The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senat
Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Influenza Vaccines Market, Persons Vaccinated, By Segment - Vaccine Type, Indication, Technology, Route of Administration, End-user, Geography, Company A
GSK to explore cancer vaccines with Oxford University in £50mln deal
04:47am, Monday, 27'th Jan 2025
GSK PLC has unveiled plans to pour £50 million into research with Oxford University over vaccines to prevent some types of cancer. A GSK-Oxford Cancer Immuno-Prevention Programme would investigate ho
New Strong Sell Stocks for January 23rd
06:40am, Thursday, 23'rd Jan 2025
ARCO, CAG and GSK have been added to the Zacks Rank #5 (Strong Sell) List on January 23, 2025.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
02:35pm, Tuesday, 21'st Jan 2025
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
10:36am, Tuesday, 21'st Jan 2025
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
08:00am, Sunday, 19'th Jan 2025
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical du
Hallucinations in AI: How GSK is addressing a critical problem in drug development
06:13pm, Tuesday, 14'th Jan 2025
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
04:00pm, Tuesday, 14'th Jan 2025
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
12:56pm, Tuesday, 14'th Jan 2025
GSK plc (NYSE:GSK ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientif
